SLC2A9 is a high-capacity urate transporter in humans.
BACKGROUND: Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have found common genetic variants of SLC2A9 to be a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2008
|
| _version_ | 1797082136135598080 |
|---|---|
| author | Caulfield, M Munroe, P O'Neill, D Witkowska, K Charchar, F Doblado, M Evans, S Eyheramendy, S Onipinla, A Howard, P Shaw-Hawkins, S Dobson, R Wallace, C Newhouse, S Brown, M Connell, J Dominiczak, A Farrall, M Lathrop, G Samani, N Kumari, M Marmot, M Brunner, E Chambers, J Elliott, P Kooner, J Laan, M Org, E Veldre, G Viigimaa, M Cappuccio, F Ji, C Iacone, R Strazzullo, P Moley, K Cheeseman, C |
| author_facet | Caulfield, M Munroe, P O'Neill, D Witkowska, K Charchar, F Doblado, M Evans, S Eyheramendy, S Onipinla, A Howard, P Shaw-Hawkins, S Dobson, R Wallace, C Newhouse, S Brown, M Connell, J Dominiczak, A Farrall, M Lathrop, G Samani, N Kumari, M Marmot, M Brunner, E Chambers, J Elliott, P Kooner, J Laan, M Org, E Veldre, G Viigimaa, M Cappuccio, F Ji, C Iacone, R Strazzullo, P Moley, K Cheeseman, C |
| author_sort | Caulfield, M |
| collection | OXFORD |
| description | BACKGROUND: Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have found common genetic variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9 gene encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed in the proximal nephron, a key site for urate handling in the kidney. We investigated whether SLC2A9 is a functional urate transporter that contributes to the longstanding association between urate and blood pressure in man. METHODS AND FINDINGS: We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200-500 microM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45- to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the uricosuric benzbromarone in a dose-dependent manner (Ki = 27 microM). Furthermore, we found urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due to SLC2A9, and not another urate transporter, we showed that urate transport was diminished by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with common variation at SLC2A9 leading to increased serum urate. We found no evidence of association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p > 0.33) by meta-analysis of an SLC2A9 variant in six case-control studies including 11,897 participants. In a separate meta-analysis of four population studies including 11,629 participants we found no association of SLC2A9 with systolic (effect size -0.12 mm Hg, 95% CI -0.68 to 0.43, p = 0.664) or diastolic blood pressure (effect size -0.03 mm Hg, 95% CI -0.39 to 0.31, p = 0.82). CONCLUSIONS: This study provides evidence that SLC2A9 splice variants act as high-capacity urate transporters and is one of the first functional characterisations of findings from genome-wide association scans. We did not find an association of the SLC2A9 gene with blood pressure in this study. Our findings suggest potential pathogenic mechanisms that could offer a new drug target for gout. |
| first_indexed | 2024-03-07T01:23:53Z |
| format | Journal article |
| id | oxford-uuid:914a8c57-26d6-442d-b95a-8b08a84b4edd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:23:53Z |
| publishDate | 2008 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:914a8c57-26d6-442d-b95a-8b08a84b4edd2022-03-26T23:17:59ZSLC2A9 is a high-capacity urate transporter in humans.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:914a8c57-26d6-442d-b95a-8b08a84b4eddEnglishSymplectic Elements at OxfordPublic Library of Science2008Caulfield, MMunroe, PO'Neill, DWitkowska, KCharchar, FDoblado, MEvans, SEyheramendy, SOnipinla, AHoward, PShaw-Hawkins, SDobson, RWallace, CNewhouse, SBrown, MConnell, JDominiczak, AFarrall, MLathrop, GSamani, NKumari, MMarmot, MBrunner, EChambers, JElliott, PKooner, JLaan, MOrg, EVeldre, GViigimaa, MCappuccio, FJi, CIacone, RStrazzullo, PMoley, KCheeseman, CBACKGROUND: Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have found common genetic variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9 gene encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed in the proximal nephron, a key site for urate handling in the kidney. We investigated whether SLC2A9 is a functional urate transporter that contributes to the longstanding association between urate and blood pressure in man. METHODS AND FINDINGS: We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200-500 microM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45- to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the uricosuric benzbromarone in a dose-dependent manner (Ki = 27 microM). Furthermore, we found urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due to SLC2A9, and not another urate transporter, we showed that urate transport was diminished by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with common variation at SLC2A9 leading to increased serum urate. We found no evidence of association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p > 0.33) by meta-analysis of an SLC2A9 variant in six case-control studies including 11,897 participants. In a separate meta-analysis of four population studies including 11,629 participants we found no association of SLC2A9 with systolic (effect size -0.12 mm Hg, 95% CI -0.68 to 0.43, p = 0.664) or diastolic blood pressure (effect size -0.03 mm Hg, 95% CI -0.39 to 0.31, p = 0.82). CONCLUSIONS: This study provides evidence that SLC2A9 splice variants act as high-capacity urate transporters and is one of the first functional characterisations of findings from genome-wide association scans. We did not find an association of the SLC2A9 gene with blood pressure in this study. Our findings suggest potential pathogenic mechanisms that could offer a new drug target for gout. |
| spellingShingle | Caulfield, M Munroe, P O'Neill, D Witkowska, K Charchar, F Doblado, M Evans, S Eyheramendy, S Onipinla, A Howard, P Shaw-Hawkins, S Dobson, R Wallace, C Newhouse, S Brown, M Connell, J Dominiczak, A Farrall, M Lathrop, G Samani, N Kumari, M Marmot, M Brunner, E Chambers, J Elliott, P Kooner, J Laan, M Org, E Veldre, G Viigimaa, M Cappuccio, F Ji, C Iacone, R Strazzullo, P Moley, K Cheeseman, C SLC2A9 is a high-capacity urate transporter in humans. |
| title | SLC2A9 is a high-capacity urate transporter in humans. |
| title_full | SLC2A9 is a high-capacity urate transporter in humans. |
| title_fullStr | SLC2A9 is a high-capacity urate transporter in humans. |
| title_full_unstemmed | SLC2A9 is a high-capacity urate transporter in humans. |
| title_short | SLC2A9 is a high-capacity urate transporter in humans. |
| title_sort | slc2a9 is a high capacity urate transporter in humans |
| work_keys_str_mv | AT caulfieldm slc2a9isahighcapacityuratetransporterinhumans AT munroep slc2a9isahighcapacityuratetransporterinhumans AT oneilld slc2a9isahighcapacityuratetransporterinhumans AT witkowskak slc2a9isahighcapacityuratetransporterinhumans AT charcharf slc2a9isahighcapacityuratetransporterinhumans AT dobladom slc2a9isahighcapacityuratetransporterinhumans AT evanss slc2a9isahighcapacityuratetransporterinhumans AT eyheramendys slc2a9isahighcapacityuratetransporterinhumans AT onipinlaa slc2a9isahighcapacityuratetransporterinhumans AT howardp slc2a9isahighcapacityuratetransporterinhumans AT shawhawkinss slc2a9isahighcapacityuratetransporterinhumans AT dobsonr slc2a9isahighcapacityuratetransporterinhumans AT wallacec slc2a9isahighcapacityuratetransporterinhumans AT newhouses slc2a9isahighcapacityuratetransporterinhumans AT brownm slc2a9isahighcapacityuratetransporterinhumans AT connellj slc2a9isahighcapacityuratetransporterinhumans AT dominiczaka slc2a9isahighcapacityuratetransporterinhumans AT farrallm slc2a9isahighcapacityuratetransporterinhumans AT lathropg slc2a9isahighcapacityuratetransporterinhumans AT samanin slc2a9isahighcapacityuratetransporterinhumans AT kumarim slc2a9isahighcapacityuratetransporterinhumans AT marmotm slc2a9isahighcapacityuratetransporterinhumans AT brunnere slc2a9isahighcapacityuratetransporterinhumans AT chambersj slc2a9isahighcapacityuratetransporterinhumans AT elliottp slc2a9isahighcapacityuratetransporterinhumans AT koonerj slc2a9isahighcapacityuratetransporterinhumans AT laanm slc2a9isahighcapacityuratetransporterinhumans AT orge slc2a9isahighcapacityuratetransporterinhumans AT veldreg slc2a9isahighcapacityuratetransporterinhumans AT viigimaam slc2a9isahighcapacityuratetransporterinhumans AT cappucciof slc2a9isahighcapacityuratetransporterinhumans AT jic slc2a9isahighcapacityuratetransporterinhumans AT iaconer slc2a9isahighcapacityuratetransporterinhumans AT strazzullop slc2a9isahighcapacityuratetransporterinhumans AT moleyk slc2a9isahighcapacityuratetransporterinhumans AT cheesemanc slc2a9isahighcapacityuratetransporterinhumans |